Skip to contentpdufa.bio

CTX-471 (CD137 agonist)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

CTX-471 (CD137 agonist) is a Compass Therapeutics, Inc. program in NCAM (CD56)-positive Grade 3 NET or NEC. Its next catalyst is a Readout in Q4 2027.

CMPX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: NCAM (CD56)-positive Grade 3 NET or NEC. Sponsor: Compass Therapeutics, Inc. (CMPX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027CMPX

Specialist biotech funds holding CMPX, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
OrbiMed Advisors15,219,994$15.8 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is CTX-471 (CD137 agonist)'s next FDA decision or readout?

The next tracked catalyst for CTX-471 (CD137 agonist) is a Readout in Q4 2027.

What happened at CTX-471 (CD137 agonist)'s most recent FDA decision?

No FDA decision for CTX-471 (CD137 agonist) is in our archive yet.

What is CTX-471 (CD137 agonist) used for?

In our records CTX-471 (CD137 agonist) is under review or in development for NCAM (CD56)-positive Grade 3 NET or NEC.

Who makes CTX-471 (CD137 agonist)?

Compass Therapeutics, Inc. (CMPX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.